Happy Independence Day 🇮🇳 — Jai Hind!

Bharat Rasayan: ₹11,499 Per Share, 66% Revenue From Just 10 Products, and 1% Dividend for Emotional Support

“For educational and entertainment purposes, not investment advice, Check disclaimer”

Bharat Rasayan: ₹11,499 Per Share, 66% Revenue From Just 10 Products, and 1% Dividend for Emotional Support

1. At a Glance

Bharat Rasayan Ltd is that low-profile nerd in class who secretly topped the board exams but refused to attend the party. A stock that trades above ₹11,000, with a market cap close to ₹4,800 Cr, yet offers a dividend yield of 0.01% — so low, it could be mistaken for a decimal error. Still, Q1FY26 net profit has more than doubled, and OPM has bounced back to 19%. Something’s brewing in this agrochemical cauldron.

2. Introduction: The Silent Assassin of Agrochemicals

No ads. No flashy investor calls. Just quiet execution. Bharat Rasayan doesn’t sell pesticides to consumers — it sells power to giants. A hardcore B2B manufacturer of technical-grade pesticides and chemical intermediates, the company is the supplier behind your favourite crop-protecting brands.

But don’t be fooled by its silence. In the last 10 years, the stock has given a 27% CAGR return — quietly compounding like a chemist in a locked lab. Now, as the chemical cycle shows signs of revival, Bharat Rasayan is crawling back into the spotlight… with ₹377 Cr in quarterly sales and a respectable ₹44 Cr PAT.

3. Business Model (WTF Do They Even Do?)

Bharat Rasayan is the chemical factory behind your favourite agrochem brand’s success. It doesn’t market fancy sachets — it sells molecules. The company produces:

  • Insecticides: Lambda Cyhalothrin, Fipronil, Thiamethoxam
  • Intermediates: Metaphenoxy Benzaldehyde, Metribuzine
  • New launches: Fluxametamide, Diuron, Tolfenpyrad

It specializes in backward-integrated manufacturing, with tight control over its supply chain. 66% of sales come from just 10 products. That’s either highly focused execution — or a concentration risk that could turn into a margin slasher overnight.

4. Financials Overview

Q1 FY26 (Standalone):

  • Revenue: ₹377 Cr (+33.7% YoY)
  • EBITDA: ₹73 Cr
  • PAT:
  • ₹44 Cr (+103% YoY)
  • EPS (Qtr): ₹105.07 → Annualized EPS ~₹420
  • Recalculated P/E: ₹11,499 / ₹420 ≈27.4x
  • ROCE: 15.4% |ROE: 12.0%

TTM Sales: ₹1,268 CrTTM PAT: ₹142 Cr

💡After two years of margin stress, FY25 and Q1FY26 show operating recovery and normalization.

5. Valuation (Fair Value RANGE only)

MethodCalculationFair Value (₹)
P/E MethodEPS ₹420 × 25–30₹10,500–₹12,600
EV/EBITDAEBITDA ₹210 Cr × 10–12₹10,000–₹12,000
DCF (Assume 10% CAGR, 11% WACC)Equity value est. ~₹4,800–5,500 Cr₹11,000–₹12,500

Fair Value Range: ₹10,000 – ₹12,600

“This FV range is for educational purposes only and is not investment advice.”

6. What’s Cooking – News, Triggers, Drama

  • Q1FY26 PAT doubledYoY — clear margin recovery
  • OPM improved to 19%from 13% in Q4FY25
  • Dividend declaredat 15% (₹1.5/share) after years of ignoring shareholders
  • Volume clarification notice from BSEin June = spike watchers beware
  • No promoter churn, no FII exits = stable ownership
  • China+1 advantageand global de-risking of chemical supply chains could help exports

7. Balance Sheet – Old School Solid

MetricFY25 (₹ Cr)
Equity Capital₹4 Cr
Reserves₹1,102 Cr
Borrowings₹85 Cr
Net Worth₹1,106 Cr
Total Assets₹1,385 Cr
This is a member-only article. Become a member
Become a member
This is a member-only article. Become a member

Leave a Comment

Popular News

error: Content is protected !!
Scroll to Top
Enable Notifications OK No thanks